top of page
Out Team
Our Research
STARLIGHT Initiative
Project PRESCIENT
PMAC Catalog

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)

    • Single cell landscape of Multicentric Castleman Disease in Identical twins

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland

    • Transcriptomic and enhancer landscape profiling identify Src-family kinase LYN as a candidate therapeutic target in human angiosarcoma​

    • Multi-omic profiling and real time ex vivo modelling of imatinib-resistant dermatofibrosarcoma protuberans with fibrosarcomatous transformation

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA

    • Therapeutic Repurposing of Brincidofovir in Natural Killer/T-cell Lymphoma Reveals Potent Induction of Replication Stress, STING Pathway Activation and Immunogenic Cell Death

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)

    • Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma​

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore

    • Precision Oncology: The Time is Now !

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea

    • ctDNA mutations in progressive gastrointestinal stromal tumors identify drug resistance biomarkers and uncover potential therapeutic strategies (Tun Kiat Ko)

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, USA

    • Identification and characterization of human angiosarcoma subtypes through multi-omic multi-dimensional profiling

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan

    • Dissecting Intratumoral Heterogeneity of Sarcomatoid RCC Arising from Autosomal Dominant Polycystic Kidney Disease (Elizabeth Lee)

  • 15 Feb 2022 : Identification of fibroblasts as key secretors of PAI-I using single cell sequencing, published in Cell Reports Medicine

  • 12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Home: Services

Start a project consultation with us

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma

Apr, 2023

Angiosarcomas are rare malignant tumors of the endothelium, arising commonly from the head and neck region (AS-HN) and recently associated with ultraviolet (UV) exposure and human herpesvirus-7 infection. We examined 81 cases of angiosarcomas, including 47 cases of AS-HN, integrating information from whole genome sequencing, gene expression profiling and spatial transcriptomics (10X Visium). In the AS-HN cohort, we observed recurrent somatic mutations in CSMD3 (18%), LRP1B (18%), MUC16 (18%), POT1 (16%) and TP53 (16%). UV-positive AS-HN harbored significantly higher tumor mutation burden than UV-negative cases (p = 0.0294). NanoString profiling identified three clusters with distinct tumor inflammation signature scores (p < 0.001). Spatial transcriptomics revealed topological profiles of the tumor microenvironment, identifying dominant but tumor-excluded inflammatory signals in immune-hot cases and immune foci even in otherwise immune-cold cases. In conclusion, spatial transcriptomics reveal the tumor immune landscape of angiosarcoma, and in combination with multi-omic information, may improve implementation of treatment strategies.

Contact us

  • LinkedIn
  • Facebook
  • Instagram

Thanks for submitting!

Home: Contact
bottom of page